Enumeration and Functional Evaluation of Regulatory T-cells in Psoriasis Patients Before and After Treatment With: Calcipotriol/Betamethasone, Acitretin, Narrow-Band UVB and Anti-TNF Alpha Therapy (Etanercept, Adalimumab and Infliximab)

NCT01233583 COMPLETED

The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-free periods develop a higher numerical ratio of regulatory to effectors T-cells and/or regulatory cells more able to suppress the effectors.

Details

Lead sponsor	University of Aberdeen
Status	COMPLETED
Enrolment	38
Start date	2010-06
Completion	2013-09

Conditions

• Psoriasis

Interventions

• Dovobet, neotigason, etanercept, adalimumab. infliximab

Primary outcomes

• Clincal-immunological correlation of treatment outcome in psoriasis patients — 12 months
  Primary outcome measures will be the first correlations of treatment outcome in psoriasis patients assessed by PASI score and PGA, with changes in the balance between Treg and effector T cells. This will test whether changes to this balance should be a major target for future therapies. In the short term, the results will also determine whether the balance provides a useful predictive biomarker for response to treatment. It is anticipated that the results will be disseminated through publications in high impact journals and presentation at relevant scientific and clinical meetings

Countries

United Kingdom